№ files_lp_4_process_2_52430
File format: docx
Character count: 9533
File size: 53 KB
The document provides instructions for the submission of cancer and tumor information to the Maryland Cancer Registry through hardcopy medical record abstracts.
Year:
2019
Region / City:
Maryland
Subject:
Cancer / Tumor Reporting
Document Type:
Instruction Manual
Organization / Institution:
Maryland Department of Health
Author:
Maryland Cancer Registry
Target Audience:
Health professionals, medical practitioners, cancer registrars
Effective Period:
Ongoing
Approval Date:
April 2019
Date of Last Modification:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / City:
San Luis Obispo, California
Topic:
PC Users Group, Windows 11, Zoom meetings, club activities
Document type:
Newsletter
Author:
Alan Raul, Ralph Sutter
Target audience:
SLO Bytes members, PC users
Effective period:
August 2021
Approval date:
July 4, 2021
Modification date:
None stated
Version:
1.5.0.0
Protocol Posting Date:
June 2024
CAP Laboratory Accreditation Program Protocol Required Use Date:
March 2025
Authors:
Gulisa Turashvili, MD, PhD; Uma G. Krishnamurti, MD, PhD; Barbara A. Crothers, DO; Giovanna A. Giannico, MD; Krisztina Hanley, MD; Anna Plotkin, MD; Anthony N. Karnezis, MD, PhD.
Note:
Accreditation Requirements
Date of Protocol Posting:
June 2024
Date of Required Use:
March 2025
Version:
4.2.0.0
Protocol Posting Date:
June 2024
Year:
2024
Region / city:
Not specified
Topic:
Bone tumor biopsy protocols
Document type:
Protocol
Organization / institution:
Not specified
Author:
Paari Murugan, MD, FCAP; Julie C. Fanburg-Smith, MD, FCAP; Andrew Horvai, MD, PhD; Fernanda Amary, MD, PhD; Meera Hameed, MD, FCAP; Michael J. Klein, MD
Target audience:
Clinicians and pathologists involved in biopsy procedures for bone tumors
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Document type:
Supplementary table
Study focus:
Representativeness of participants with HER2-positive solid tumors
Cancer type:
HER2-Positive Solid Tumors
Countries involved:
Spain, United Kingdom, Germany
Sample size:
18 participants
Sex distribution:
4 male (22 %), 14 female (78 %)
Median age:
63 years
Age range:
46–77 years
Tumor types represented:
Breast cancer, Uterus cancer, Stomach cancer, Colorectal cancer, Paget’s disease extramammary, Gastroesophageal cancer
HER2 positivity definition:
IHC 3+
Geographical scope of epidemiological context:
Worldwide, United States, Europe
Data sources cited:
Global Cancer Observatory; SEER Program; National Cancer Institute; Eurostat; National Center for Health Statistics; JAMA Oncology
Access date of cited online sources:
3rd September 2025
Version:
5.0.0.0
Protocol Posting Date:
December 2023
CAP Laboratory Accreditation Program Protocol Required Use Date:
September 2024
Authors:
Dhanpat Jain, MD; William V. Chopp, MD; Rondell P. Graham, MBBS
Accreditation Requirements:
Core data elements required for clinical care and accreditation purposes. Optional data elements for reporting as determined by local standards.
Procedure:
Resection, biopsy, excision biopsy
Tumor Type:
Well-differentiated neuroendocrine tumor
Year:
2017
Region / City:
N/A
Topic:
Retinoblastoma, Germ Cell Tumors, Hepatoblastoma
Document Type:
Medical Case Study
Organization / Institution:
N/A
Author:
Carlos Rodriguez-Galindo, MDA
Target Audience:
Medical Professionals
Period of Action:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2024
Region / City:
N/A
Topic:
Medical protocol
Document Type:
Protocol
Organization / Institution:
CAP Laboratory Accreditation Program
Authors:
Julie C. Fanburg-Smith, MD, FCAP; Paari Murugan, MD, FCAP; Andrew Horvai, MD, PhD; Fernanda Amary, MD, PhD; Meera Hameed, MD, FCAP; Michael J. Klein, MD.
Target Audience:
Pathologists, medical professionals in oncology
Effective Period:
March 2025
Approval Date:
June 2024
Date of Changes:
June 2024
Year:
2023
Region / city:
Wuhan, China
Topic:
Medical Imaging, Artificial Intelligence, Gastrointestinal Stromal Tumors
Document Type:
Research Article
Organization / Institution:
Renmin Hospital of Wuhan University
Authors:
Chenxia Zhang, Wei Tan, Xun Li, Xiao Tao, Bing Xiao, Wei Zhou, Honggang Yu
Target Audience:
Medical professionals, researchers in gastroenterology and artificial intelligence
Period of Application:
Not specified
Date of Approval:
Not specified
Date of Changes:
Not specified
Keywords:
Gastrointestinal Stromal Tumors, Endoscopic Ultrasound, Artificial Intelligence, Risk Stratification, Deep Learning
Methodology:
Image Classification, Image Segmentation, Deep Convolutional Neural Network (DCNN), ResNet, Unet++
Evaluation Metrics:
Accuracy, Intersection over Union (IoU), Precision, Recall, F1 score
Conclusion:
The use of AI-based risk stratification and image analysis improves GIST diagnosis accuracy
References:
Li J, Zhu Y, Dong Z, et al., Yao L, Zhang J, Liu J, et al., Zhou Z, Siddiquee MMR, Tajbakhsh N, Liang J
Document type:
Supplementary tables and figures
Subject:
Proton therapy and VMAT treatment planning and dosimetric analysis
Techniques evaluated:
IMPT, VMAT
Clinical indications:
Base of skull tumors, paediatric craniopharyngioma, chordoma, chondrosarcoma
Structures analyzed:
Brain, Brainstem, Optic chiasm, Optic nerves, CTV
Dose metrics:
Mean dose, Maximum dose, EQD2, BED, LETd
Robustness parameters:
Isocenter shifts ±3.0 mm; Proton range uncertainty ±3.5%
Fractionation scheme:
1.67 Gy(RBE) fractions
Constraint source:
EPTN dose constraints
Number of patients:
6 adult cases
Comparative models:
Nominal IMPT, Worst case IMPT uncertainty, VMAT, McNamara variable RBE model (α/β)x = 2–4 Gy
Figures included:
Beam arrangement views, dose distributions, LETd maps, DVHs, robustness analysis
Year:
2026
Region / City:
International / Multiple research institutions
Subject:
Cancer immunotherapy, tumor microenvironment
Document type:
Supplementary scientific data
Institution:
University of Southampton, Genkyotex SA, La Jolla Institute for Allergy & Immunology, University of Toronto, University of Kent
Authors:
Kirsty Ford, Christopher J. Hanley, Massimiliano Mellone, Cedric Szyndralewiez, Freddy Heitz, Philippe Wiesel, Oliver Wood, Maria Machado, Monette Lopez, Anusha-Preethi Ganesan, Chuan Wang, Ankur Chakravarthy, Tim Fenton, Emma V. King, Pandurangan Vijayanand, Christian H. Ottensmeier, Aymen Al-Shamkhani, Natalia Savelyeva, Gareth J. Thomas
Target audience:
Researchers in oncology and immunology
Data type:
Figures, tables, and experimental results
Methods:
Q-PCR, immunofluorescence, IHC, RNA sequencing, gene network analysis
Experimental models:
Murine syngeneic tumors, TC1, MC38, 4T1, BALBneuT breast tumors
Treatment tested:
NOX4 inhibition, TGF-β1 inhibition, αPD-1, αCTLA-4, macrophage depletion
Key focus:
CAF-mediated CD8 T-cell exclusion, tumor growth modulation, immunotherapy response
Supplementary content:
Figures S1–S6, Tables S1–S2
Year:
2023
Region / City:
Not specified
Subject:
Pathology, Neuroendocrine Tumors
Document Type:
Clinical Protocol
Organization / Institution:
College of American Pathologists (CAP)
Authors:
Dhanpat Jain, MD; William V. Chopp, MD; Rondell P. Graham, MBBS
Target Audience:
Pathologists, Laboratory Personnel
Effective Period:
September 2024
Protocol Version:
2.0.0.0
Procedures Covered:
Segmental resection, Ileocolic resection
Tumor Types Covered:
Well-differentiated neuroendocrine tumors of the jejunum and ileum
Accreditation Required:
Yes, for primary resection specimens
Exclusions:
Biopsies, recurrent tumors, metastatic tumors, duodenum/ampulla tumors, poorly differentiated NEC, non-GIST sarcomas, lymphomas, GIST
Synoptic Reporting:
Core and conditional data elements required
Histologic Grades:
G1, G2, G3, GX
Data Elements:
Tumor size, focality, mitotic rate, Ki-67 labeling index, pathologic stage, margins
Summary of Changes:
AJCC 9 pTNM staging, WHO 5th Edition updates, lymphovascular invasion updated
Year:
2021
Study type:
Clinical research
Document type:
Supplementary materials
Authors:
Not specified
Institution:
Not specified
Target audience:
Researchers in oncology and virology
Tumor types:
Glioma, Meningioma, Pituitary adenoma, Craniopharyngioma, Ependymoma, Schwannoma, Haemangioblastoma, Chordoma, Brain metastases from breast, lung, kidney, colon cancer
Methods:
Immunohistochemistry, Immunofluorescence, Gene expression analysis, KEGG enrichment, GSEA
Patient information:
Age, Sex, Preexisting conditions, Preoperative treatment, SARS-CoV-2 PCR status
Figures included:
S1–S6
Tables included:
S1
Key markers analyzed:
ACE2, TMPRSS2, CD147, NRP1, IFN-γ, PD-1, FOXP3, CD8, CD4, C1q, C3, IgG, IgM, CD68, TTF1, MUC1
Year:
Not specified
Region / City:
Not specified
Topic:
Tumor analysis, prostate cancer (PC), ISUP classification
Document Type:
Research table
Institution / Organization:
Not specified
Author:
Not specified
Target Audience:
Researchers, medical professionals
Period of Action:
Not specified
Date of Approval:
Not specified
Date of Modifications:
Not specified
Context:
A research table comparing tumor samples of prostate cancer patients classified by ISUP scores and their chemical shift variables.
Year:
2023
Journal:
World Journal of Gastrointestinal Oncology
Manuscript Number:
86810
Type:
Review
Authors:
Guo-Qing Chen, Yi Nan, Shi-Cong Huang, Na Ning, Yu-Hua Du, Dou-Dou Lu, Ya-Ting Yang, Fan-Di Meng, Ling Yuan
Affiliations:
College of Pharmacy, Ningxia Medical College; Key Laboratory of Ningxia Ethnomedicine Modernization, Ministry of Education, Ningxia Medical University; Traditional Chinese Medicine College, Ningxia Medical University; School of Clinical Medicine College, Ningxia Medical University
Funding:
Young Scholars of Western China, West Light Foundation of the Chinese Academy of Sciences (No. XAB2019AW13); Ningxia Natural Science Foundation (No. 2022AAC02039)
Corresponding Author:
Ling Yuan, PhD, College of Pharmacy, Ningxia Medical College, Yinchuan, Ningxia Hui Autonomous Region, China
Received:
July 9, 2023
Revised:
September 15, 2023
Accepted:
Not specified
Published Online:
Not specified
Keywords:
Ginger, Medicine and food homology, Gastrointestinal cancer, Molecular mechanism
Scope:
Review of pharmacological effects and clinical potential of ginger on gastrointestinal tumors
Year:
2024
Region / city:
Seattle, WA, United States
Subject:
Medical Imaging, Radiology, Oncology
Document type:
Journal article
Institution:
University of Washington School of Medicine
Author:
Woongsoon John Choi, Peggy Lee, Penelope C Thomas, Tanya J Rath, Monique A Mogensen, Roberta W Dalley, Pattana Wangaryattawanich
Target audience:
Radiologists, Oral Surgeons, Healthcare professionals
Period of validity:
2024
Date of approval:
August 27, 2024
Date of revisions:
August 22, 2024
Date of publication:
August 28, 2024
Year:
2026
Region / City:
Not specified
Topic:
Small Cell Lung Cancer, Gene Expression
Document Type:
Supplementary Figure / Research Data
Institution:
GTEx, Amgen
Methodology:
RNA-Seq, Immunohistochemistry, Flow Cytometry
Sample Size:
28 SCLC tumor samples, 3,789 GTEx normal tissue samples, 518 Amgen normal tissue samples
Markers:
DLL3
Data Visualization:
Log2 FPKM + 0.1, Photomicrographs
Experimental Details:
Secondary antibody controls included